ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RENE Reneuron Group Plc

3.05
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 530k -5.41M -0.0946 -0.32 1.74M
Reneuron Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 3.05p. Over the last year, Reneuron shares have traded in a share price range of 2.95p to 10.25p.

Reneuron currently has 57,173,760 shares in issue. The market capitalisation of Reneuron is £1.74 million. Reneuron has a price to earnings ratio (PE ratio) of -0.32.

Reneuron Share Discussion Threads

Showing 8751 to 8771 of 8900 messages
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older
DateSubjectAuthorDiscuss
22/6/2023
13:00
570k buy someone's very confident.
avsome1968
19/6/2023
15:17
I'm enjoying the ride but we are now at a price that suggests the probability of success in the in vitro trials is rising. RENE has failed with two products in the past. Fingers crossed for 3rd time lucky rather than 3rd strike and you're out.
dickbush
16/6/2023
17:42
so theyve spent about 12k each laughable
fred177
16/6/2023
17:29
Share Purchase by Senior Independent Non-executive Director

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Barbara Staehelin, Senior Independent Non-executive Director of the Company, has today purchased 150,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

xow98
16/6/2023
14:32
Share Purchase by Executive Chairman

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Iain Ross, Executive Chairman of the Company, has today purchased 150,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

xow98
26/5/2023
14:45
Seems the 'investormeet' went down swimmingly.
glavey
25/5/2023
22:13
IMC today.

"Reneuron is NOT going bust"

"£35m fair value in the analyst report"

Current market cap - £3.6m

nigelpm
25/5/2023
14:02
However, there is no guarantee that attempts to secure adequate cash inflows from the Group's exosome platform, IP and legacy assets or through equity fund raising with the timescales stated above will be successful. These conditions indicate the existence of a material uncertainty, which may cast significant doubt about the Group's and Company's ability to continue as a going concern.
terminator101
25/5/2023
13:14
It looks like Obotritia Capital is providing a tap. I just bought some at very close to the bid price. It's marked as a sale.
dickbush
25/5/2023
09:17
Switched to HARL at good time
blackhorse23
25/5/2023
09:16
Require placing or bust
blackhorse23
25/5/2023
07:36
You reading the same results as me??
babbler
25/5/2023
07:19
Horror show results.

Fundraising incoming.

terminator101
23/5/2023
09:51
Agreed. Money you can lose. But could be good.
richtea2517
18/5/2023
10:28
Investor presentation

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023.

Investor Briefing

Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 9:30am BST on Thursday 25 May 2023. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:



Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

thiopia
16/5/2023
21:57
That's exactly the punt - a large one but could come off.
nigelpm
16/5/2023
19:24
This now looks interesting. Market cap of £4m and holds cash of around £6m. Some recent buying by Directors and NED. They have a cash runway into 2024 to be able to commercialise their exosome platform. Share price about 7p and brokers have targets around 70p. Seems high risk / high reward opportunity? I have made a small investment today that I am prepared to lose 100% of it. Be interesting to see what happens over the next 6 to 9 months.
pdt
06/5/2023
18:01
Just checking in on this pile of lifestyle scientist pedestrian pish. Plus ca change huh. Zzzzzzzzzzz
terminator101
06/4/2023
16:26
Wow mom exec director spends 4.5 k on shares must be about to fly NOT at least put your full new ISA allowance if you have any confidence at all which I don’t
fred177
28/3/2023
14:48
Seems that Ross' purchase today showing as a sell. Encouraging confidence though.
small crow
03/3/2023
16:14
Just bought OK
red army
Chat Pages: 356  355  354  353  352  351  350  349  348  347  346  345  Older

Your Recent History

Delayed Upgrade Clock